Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection

Alimentary Pharmacology and Therapeutics

Volumn 40, Issue 6, 2014, Pages 657-675

  Saab, S ^a   Gordon, S C ^b   Park, H ^c   Sulkowski, M ^d   Ahmed, A ^e   Younossi, Z ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HENRY FORD HEALTH SYSTEM   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^f BETTY AND GUY BEATTY CENTER FOR INTEGRATED RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; BOCEPREVIR; PEGINTERFERON; PEGINTERFERON 2A; PEGINTERFERON 2B; RECOMBINANT INTERFERON; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DRUG COST; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MIXED INFECTION; MONOTHERAPY; OUTCOME ASSESSMENT; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SUSTAINED VIROLOGICAL RESPONSE; UNITED STATES;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DRUG THERAPY, COMBINATION; GENOTYPE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HETEROCYCLIC COMPOUNDS, 3-RING; HIV INFECTIONS; HUMANS; INTERFERON-ALPHA; LIVER CIRRHOSIS; MIDDLE AGED; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; RIBAVIRIN; SULFONAMIDES; URIDINE MONOPHOSPHATE;

EID: 84906218627     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12871     Document Type: Article

References (92)

1. Gordon SC, Pockros PJ, Terrault NA, et al,. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. Hepatology 2012; 56: 1651-60.
2. McCombs JS, Yuan Y, Shin J, et al,. Economic burden associated with patients diagnosed with hepatitis C. Clin Ther 2011; 33: 1268-80.
3. Younossi ZM, Kanwal F, Saab S, et al,. The impact of hepatitis C burden: an evidence-based approach. Aliment Pharmacol Ther 2014; 39: 518-31.
4. Gordon SC, Hamzeh FM, Pockros PJ, et al,. Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther 2013; 38: 784-93.
5. Hagan LM, Schinazi RF,. Best strategies for global HCV eradication. Liver Int 2013; 33 (Suppl. 1): 68-79.
6. Soriano V, Sulkowski M, Bergin C, et al,. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS 2002; 16: 813-28.
7. Kim AY, Chung RT,. Coinfection with HIV-1 and HCV- one-two punch. Gastroenterology 2009; 137: 795-814.
8. Hadigan C, Kottilil S,. Hepatitis C virus infection and coinfection with human immunodeficiency virus: challenges and advancements in management. JAMA 2011; 306: 294-301.
9. Ghany MG, Strader DB, Thomas DL, et al,. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
10. Haque M, Yoshida EM,. Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Ann Hepatol 2009; 8: 78-9.
11. Nainan OV, Alter MJ, Kruszon-Moran D, et al,. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 2006; 131: 478-84.
12. Ghany MG, Nelson DR, Strader DB, et al,. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-44.
13. Poordad F, McCone J Jr, Bacon BR, et al,. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-206.
14. Jacobson IM, McHutchison JG, Dusheiko G, et al,. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
15. Shiffman ML, Suter F, Bacon BR, et al,. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.
16. Fried MW, Shiffman ML, Reddy KR, et al,. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.
17. Nelson DR,. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients. Liver Int 2011; 31 (Suppl. 1): 53-7.
18. Falck-Ytter Y, Kale H, Mullen KD, et al,. Surprisingly small effect of antiviral treatment in patients with hepatitis C. Ann Intern Med 2002; 136: 288-92.
19. Hezode C, Fontaine H, Dorival C, et al,. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC)-NCT01514890. J Hepatol 2013; 59: 434-41.
20. Davis GL, Albright JE, Cook SF, et al,. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-8.
21. Sethi N, Vong A, Firdoos S, et al,. Analysis of direct and indirect costs of HCV care with PEG-Interferon triple therapy. Oral presentation at the Liver Meeting: the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013. Washington, DC. Presentation no. 1847.
22. Bichoupan K, Martel-Laferriere V, Ng M, et al,. Real world costs of telaprevir-based triple therapy, including costs of managing adverse events, at the Mount Sinai Medical Center, NY: 195,000 per SVR12. Heptology 2013; 558 (Suppl.): 329A-30A.
23. Vaidya A, Perry CM,. Simeprevir: first global approval. Drugs 2013; 73: 2093-106.
24. Dieterich D, Rockstroh J, Orkin C, et al,. Simeprevir (TMC435) in combination with peginterferon/ribavirin in patients co-infected with HCV genotype and HIV-1: primary analysis of the C212 study. 14th European AIDS Conference 2013, 16-19 October, 2013. Brussels, Belgium.
25. Janssen. Briefing Document. Simeprevir (TMC435) treatment of patients with chronic hepatitis C, 2013. Available at: http://www.fda.gov/downloads/ Advisorycommittees/Committeesmeetingmaterials/Drugs/ Antiviraldrugsadvisorycommittee/ucm371624.pdf. Accessed March 2014.
26. Fried MW, Buti M, Dore GJ, et al,. Once-daily simeprevir (TMC435) with pegylated interferon and ribavirin in treatment-naive genotype 1 hepatitis C: the randomized PILLAR study. Hepatology 2013; 58: 1918-29.
27. Lawitz E, Mangia A, Wyles D, et al,. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med 2013; 368: 1879-87.
28. Koff RS,. Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection. Aliment Pharmacol Ther 2014; 39: 478-87.
29. Jacobson IM, Gordon SC, Kowdley KV, et al,. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med 2013; 368: 1867-77.
30. Gane EJ, Stedman CA, Hyland RH, et al,. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013; 368: 34-44.
31. American Association for the Study of Liver Diseases (AASLD) & Infectious Disease Society of America (IDSA). Recommendations for testing, managing, and treating hepatitis C, 2014. Available at: http://www. hcvguidelines.org/full-report-view. Accessed March 2014.
32. Chhatwal J, Ferrante SA, Brass C, et al,. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health 2013; 16: 973-86.
33. Cure S, Bianic F, Gavart S, et al,. Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in previously untreated chronic hepatitis C genotype 1 patients. J Med Econ 2014; 17: 65-76.
34. Hagan LM, Yang Z, Ehteshami M, et al,. All-oral, interferon-free treatment for chronic hepatitis C: cost-effectiveness analyses. J Viral Hepat 2013; 20: 847-57.
35. Younossi ZM, Singer ME, Mir HM, et al,. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients. J Hepatol 2014; 60: 530-5.
36. Hartwell D, Jones J, Baxter L, et al,. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation. Health Technol Assess 2011; 15: 1-210.
37. Davis GL, Alter MJ, El-Serag H, et al,. Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010; 138: 513-21.
38. Sulkowski MS, Rodriguez-Torres M, Lalezari JP, et al,. All-oral therapy with sofosbuvir plus ribavirin for the treatment of HCV genotype 1, 2, and 3 infection in patients co-infected with HIV (PHOTON-1). Oral presentation at the Liver Meeting: the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013. Washington, DC. Presentation no. 212.
39. Rodriguez-Torres M, Rodriguez-Orengo J, Gagger A, et al,. Sofosbuvir and peginterferon alfa-2a/ribavirin for treatment-naïve genotype 1-4 HCV-infected patients who are coinfected with HIV. Poster presented at IDWeek 2013; October 2-6, 2013. San Francisco, CA. Poster no. 714.
40. Bacon BR, Khalid O,. New therapies for hepatitis C virus infection. Mol Med 2011; 108: 255-9.
41. Bruno S, Shiffman ML, Roberts SK, et al,. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 2010; 51: 388-97.
42. Dieterich D, Soriano V, Sherman K, et al,. Telaprevir in combination with peginterferon alfa-2a/ribavirin in hepatitis C/HIV co-infected patients: a 24-week treatment interim analysis. 19th Conference on Retroviruses and Opportunistic Infections. March 5-8, 2012. Seattle, WA. Abstract no. 46.
43. Poynard T, Colombo M, Bruix J, et al,. Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy. Gastroenterology 2009; 136: 1618-28.
44. Sulkowski MS, Pol S, Cooper C, et al,. Boceprevir plus peginterferon/ribavirin for the treatment of hepatitis C/HIV co-infected patients. 19th Annual Conference on Retroviruses and Opportunistic Infections, March 5-8, 2012. Seattle, WA. Abstract no. 47.
45. Sulkowski MS, Sherman KE, Dieterich DT, et al,. Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 2013; 159: 86-96.
46. Sulkowski MS, Pol S, Mallolas J, et al,. Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 2013; 13: 597-605.
47. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al,. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438-50.
48. Zeuzem S, Andreone P, Pol S, et al,. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-28.
49. Krawitt EL, Ashikaga T, Gordon SR, et al,. Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C. J Hepatol 2005; 43: 243-9.
50. Jacobson IM, Marcellin P, Zeuzem S, et al,. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 2012; 56: 567-75.
51. Roberts SK, Weltman MD, Crawford DH, et al,. Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial. Hepatology 2009; 50: 1045-55.
52. Gordon SC, Muir AJ, Lim JK,. The frequency and management of adverse events in chronic hepatitis C (HCV) treated with boceprevir or telaprevir: real world experience from HCV-TARGET longitudinal observational study. Hepatology 2013; 58 (Suppl. 1): 1104A.
53. Sherman KE, Flamm SL, Afdhal NH, et al,. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-24.
54. Lawitz E, Gane E, Stedman C, et al,. GS-7977 phase II trials: concordance of SVR4 with SVR12 and SVR24 in HCV genotypes 1-3. J Hepatol 2012; 56 (Suppl. 2): S4.
55. Gilead Sciences Inc. Briefing document: sofosbuvir for treatment of chronic hepatitis C infection. Submitted to the FDA Antiviral Drugs Advisory Committee. 25 October 2013. Available at: http://www.fda.gov/downloads/ AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ AntiviralDrugsAdvisoryCommittee/UCM252562.pdf. Accessed December 6, 2013.
56. Sovaldi Prescribing Information. Clinical trials in subjects with genotype 1 or 4 CHC (14.2). Available at: http://www.gilead.com/~/media/Files/ pdfs/medicines/liverdisease/sovaldi/sovaldi-pi.pdf. Accessed March 25, 2014.
57. Chen J, Florian J, Carter W, et al,. Earlier sustained virologic response end points for regulatory approval and dose selection of hepatitis C therapies. Gastroenterology 2013; 144: 1450-5.
58. Lawitz E, Gane EJ, Lalezari J, et al,. High concordance of SVR4, SVR12, and SVR24 in patients with HCV infection who have received treatment with sofosbuvir. EASL 48th Annual Meeting, April 24-28, 2013, Amsterdam, the Netherlands.
59. Zein NN,. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 2000; 13: 223-35.
60. Lenz O, Fevery B, Verbinnen T, et al,. Resistance analyses of HCV isolates from patients treated with simeprevir in Phase IIB/III studies. 64th Annual Meeting of the America Association for the Study of Liver Diseases, November 1-5, 2013, Washington, DC, USA.
61. Toyoda H, Kumada T,. Pharmacotherapy of chronic hepatitis C virus infection-the IDEAL trial: '2b or not 2b (= 2a), that is the question'. Expert Opin Pharmacother 2009; 10: 2845-57.
62. Thein HH, Yi Q, Dore GJ, et al,. Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression. Hepatology 2008; 48: 418-31.
63. Razavi H, Elkhoury AC, Elbasha E, et al,. Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology 2013; 57: 2164-70.
64. Liu S, Cipriano LE, Holodniy M, et al,. New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med 2012; 156: 279-90.
65. Murphy SL, Xu JQ, Kochanek KD,. Division of Vital Statistics. Deaths: final data for 2010. Table 3. Number of deaths and death rates, by age, race, and sex: United States, 2010. National Vital Statistics Reports, vol. 61, no. 4, May 2013. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr61/nvsr61-04.pdf. Accessed July 16, 2013.
66. Graham CS, Baden LR, Yu E, et al,. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33: 562-9.
67. Kuehne FC, Bethe U, Freedberg K, et al,. Treatment for hepatitis C virus in human immunodeficiency virus-infected patients: clinical benefits and cost-effectiveness. Arch Intern Med 2002; 162: 2545-56.
68. Hornberger J, Torriani FJ, Dieterich DT, et al,. Cost-effectiveness of peginterferon alfa-2a (40 kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection. J Clin Virol 2006; 36: 283-91.
69. Terrault NA, Roland ME, Schiano T, et al,. Outcomes of liver transplant recipients with hepatitis C and human immunodeficiency virus coinfection. Liver Transpl 2012; 18: 716-26.
70. de Vera ME, Dvorchik I, Tom K, et al,. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 2983-93.
71. Ragni MV, Belle SH, Im K, et al,. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis 2003; 188: 1412-20.
72. Bureau of Labor Statistics. US Department of Labor. Consumer Price Index-all urban consumers (current series), July 2013. Available at: http://data.bls.gov/cgi-bin/surveymost?cu. Accessed July 16, 2013.
73. Resource-Based Relative Values Scale (R-BRVS). The Essential RBRVS: A Comprehensive Listing of RBRVS Values for CPT and HCPCS Codes. Salt Lake City, UT, USA: Optum Insight Inc, 2013.
74. Red Book Online. Micromedex 2.0. Available at: http://www. micromedexsolutions.com/home/dispatch. Accessed December 12, 2013.
75. Campos NG, Salomon JA, Servoss JC, et al,. Cost-effectiveness of treatment for hepatitis C in an urban cohort co-infected with HIV. Am J Med 2007; 120: 272-9.
76. Thein HH, Krahn M, Kaldor JM, et al,. Estimation of utilities for chronic hepatitis C from SF-36 scores. Am J Gastroenterol 2005; 100: 643-51.
77. Younossi ZM, Stepanova M, Nader F, et al,. Health utilities in patients with chronic hepatitis C treated with sofosbuvir (SOF) containing regimens: results from POSITRON, FISSION, FUSION and NEUTRINO studies. Hepatology 2013; 58 (Suppl.): 385.
78. Gold MR, Siegel JE, Russell LB, et al,. Cost-Effectiveness in Health and Medicine. New York: Oxford University Press, 1996.
79. Blazquez-Perez A, San Miguel R, Mar J,. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients. Pharmacoeconomics 2013; 31: 919-31.
80. Bichoupan K, Martel-Laferriere V, Sachs D, et al,. Costs of telaprevir-based triple therapy including adverse event management at the Mount Sinai Medical Center, NY 189,000 per SVR. Oral presentation at the Liver Meeting: the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013. Washington, DC. Presentation no. 244.
81. Mandelblatt JS, Lawrence WF, Womack SM, et al,. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 2372-81.
82. Lindfors KK, Rosenquist CJ,. The cost-effectiveness of mammographic screening strategies. JAMA 1995; 274: 881-4.
83. Ngygen MH, Brooks L, Livornese RC,. Suboptimal treatment rates and treatment completion rates of chronic hepatitis C virus therapy in patients with comorbidities: analysis of a large real-world US cohort. Poster presented at the Liver Meeting: the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013. Washington, DC. Poster no. 2040.
84. Backus LI, Belperio PS, Shahoumian TA, et al,. Comparative effectiveness of the hepatitis C virus protease inhibitors boceprevir and telaprevir in a large U.S. cohort. Aliment Pharmacol Ther 2014; 39: 93-103.
85. Poynard T, Moussalli J, Munteanu M, et al,. Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 2013; 59: 675-83.
86. Zeuzem S, Dusheiko GM, Salupere R, et al,. Sofosbuvir + ribavirin for 12 or 24 weeks for patients with HCV genotype 2 or 3: the VALENCE Trial. Poster presented at the Liver Meeting: the 64th Annual Meeting of the American Association for the Study of Liver Diseases; November 1-5, 2013. Washington, DC. Poster no. 1085.
87. Probst A, Dang T, Bochud M, et al,. Role of hepatitis C virus genotype 3 in liver fibrosis progression-a systematic review and meta-analysis. J Viral Hepat 2011; 18: 745-59.
88. McAdam-Marx C, McGarry LJ, Hane CA, et al,. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the United States: a managed care perspective. J Manag Care Pharm 2011; 17: 531-46.
89. Chong CA, Gulamhussein A, Heathcote EJ, et al,. Health-state utilities and quality of life in hepatitis C patients. Am J Gastroenterol 2003; 98: 630-8.
90. McLernon DJ, Dillon J, Donnan PT,. Health-state utilities in liver disease: a systematic review. Med Decis Making 2008; 28: 582-92.
91. Hsu PC, Federico CA, Krajden M, et al,. Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol 2012; 27: 149-57.
92. Wright M, Grieve R, Roberts J, et al,. Health benefits of antiviral therapy for mild chronic hepatitis C: randomized controlled trial and economic evaluation. Health Technol Assess 2006; 10: 1-113.